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Inflow Thrombosis Does Not Adversely Affect Thrombolysis Out-
comes of Symptomatic Iliofemoral Deep Venous Thrombosis
G. Jeyabalan, G. Konig, L. Marone, R. Rhee, M. Makaroun, J. Cho, and
R. Chaer, Pittsburgh, Pa
From the University of Pittsburgh Medical Center.
Background: The presence of popliteal or tibial vein clot is thought to
adversely affect thrombolysis for iliofemoral deep venous thrombosis (DVT). We
examined the effect of inflow thrombosis on functional and anatomic outcomes.
Methods: A retrospective review of 44 patients treated for symptom-
atic iliofemoral DVT between 2006 and 2009 was performed. All patients
were treated by pharmacomechanical thrombectomy with local tissue plas-
minogen activator with the Angiojet or Trellis device. Catheter-directed lysis
and vena cava filters were used sparingly. Univariate and multivariate logistic
regression analyses were used.
Results: Forty-four patients with a mean age of 52.1  15.8 years
presented with symptoms averaging 13.4  9.9 days in duration. Twenty
(45.4%) had symptoms for 14 days; 39% were treated in one session, but 27
patients required lytic infusion for residual thrombus. Iliac stentingwas required
in 49% of limbs. Successful lysis (50%) was achieved in 91% of patients, and
symptom resolution or improvement in 91%. All patients became ambulatory
with no or minimal limitation. No major systemic bleeding complications
occurred. Freedom from DVT recurrence and reintervention was 84% at 24
months by life-table analysis. On preoperative ultrasound imaging, 89% had
popliteal and tibial clot and were treated by accessing a thrombosed popliteal
vein. Only one patient required simultaneous tibial lysis. At amean follow-up of
8.7  6.3 months, 41 patients (93%) had no symptom recurrence (Fig), 82%
had preserved valve function and no reflux on duplex imaging, with a mean
CEAP class of 1.4. The presence of inflow thrombus had no adverse effect on
symptom relief, treatment duration, patency, CEAP class, or valve reflux.
Interestingly, 90% of patients with initial popliteal thrombus had a patent
popliteal vein on postlysis ultrasound imaging, and the presence of tibial
thrombus on presentation was predictive of symptom relief with thrombolysis
(odds ratio, 13.03; 95% confidence interval, 1.02-165.58; P .048).
Conclusions: Inflow thrombosis is common and does not preclude
successful thrombolysis of iliofemoral DVT. Valve function is preserved on
midterm follow-up with maintained CEAP class and symptom relief.
Objective Outcome Measures of Patients with Iliofemoral Deep Venous
Thrombosis Treated with Catheter-directed Thrombolysis
N. K. Grewal,a J. Trabal Martinez,a L. Andrews,a Z. Assi,b S. Kasanjian,b and
A. J. Comerota,a Toledo, Ohio
From the Jobst Vascular Center,a and Interventional Radiology,b The
Toledo Hospital.
Background: It has been suggested that elimination of thrombus in
patients with iliofemoral deep venous thrombosis (DVT)may reduce the risk
of the post-thrombotic syndrome (PTS). The purpose of this study was to
provide objective follow-up in patients treated with pharmacomechanical
thrombolysis or catheter-directed thrombolysis for extensive lower extrem-
ity DVT.
Methods: Patients with iliofemoral DVT who underwent catheter-
directed or pharmacomechanical thrombolysis were monitored and assessed
for signs and symptoms of PTS using validated outcome measures: the
CEAP clinical classification, the Villalta score, and the Venous Clinical
Severity Score (VCSS).
Results: Forty-eight patients underwent catheter-based treatment for
iliofemoral DVT, 21 with catheter-directed thrombolysis and 27 with phar-
macomechanical lysis. The average patient age was 46 years (range, 16-78
years). Mean percentage of clot lysis as determined by preprocedural and
postprocedural venography was 76%. Follow-up averaged 21.3 months.
Mean clinical class of CEAP and VCSS and Villalta scores were 2, 3, and 4,
respectively. Complications of thrombolysis included one acute renal failure
and two major hematomas. No intracranial bleeding or symptomatic pul-
monary embolism occurred.
Conclusions: Patients with iliofemoral DVT who underwent cath-
eter-based thrombolytic techniques to eliminate thrombus demonstrated
good technical results based on the percentage of clot lysis. This resulted
in overall good clinical scores based on the CEAP, VCSS, and Villalta
validated scoring systems. PTS was avoided as defined by the Villalta
score. These observations indicate a successful strategy of catheter-
directed thrombolysis will likely prevent the development of PTS or
substantially reduce its severity.
Anticoagulation Monitoring by an Anticoagulation Service is More
Cost-effective than Routine Physician Care
F. Aziz, M. Corder, and A. J. Comerota, Toledo, Ohio
From the Jobst Vascular Center, The Toledo Hospital.
Background: Vitamin K antagonists (VKA) are the mainstay of long-
term anticoagulation but require careful monitoring for effectiveness and
safety. Most patients are treated by physicians, although anticoagulation
services (AS) are becoming increasingly popular. A newAS run by nurses and
overseen by a physician was established, and the insurance carrier indepen-
dently assessed its effectiveness vs usual physician care. We report the
independent analysis of anticoagulation morbidity reflected by emergency
department (ED) visits and hospitalizations observed by these two para-
digms of VKA monitoring.
Methods: An independent analysis of ED visits and hospitalizations as
a consequence of anticoagulation was performed for 2397 patients receiving
VKA between July 1 and December 31, 2008. Physicians monitored 2266
patients and the newly formed AS monitored 133. The average cost of ED
visits and hospitalizations was calculated for each patient cohort. The
expense of each was amortized for 12 months to determine an annual cost of
anticoagulation morbidity per 100 patients treated.
Results: Results are summarized in the Table.
Table. Six-month data for emergency department visits
and hospitalizations related to anticoagulation
Variable
Monitoring service
TotalMD AS
Patients evaluated,
No. (%)
2266
(94.5)
131 (5.5) 2397
Emergency
department data
Visits, No. (%) 247 (10.9) 2 (1.5) 249 (12.4)
Cost per visit $288.00 $139.00
Cost per patient
treated
$31.00 $2.00
Savings per patient
treated by AS
$29.00
Annual savings/100
patients treated
$5800.00
Hospitalization data
Fig. Freedom from symptom recurrence after thrombosis for
iliofemoral DVT
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